FAS managed to decrease 239 prices on the drugs for treating HIV, tuberculosis, hepatitis B and C

The minimum saving of budgetary funds from reducing prices will reach over 63 million RUB for the Ministry of health Care for HIV-treatment drugs

As a result of Stage II of the international comparative analysis of medicinal drug prices, carried out by FAS upon an order of the president of the Russian Federation, pharmaceutical manufacturers voluntarily decrease 239 prices on the drugs for treating HIV, tuberculosis, hepatitis B and C.

112 prices went down based on the outcome of Stage II of the study – international monitoring of prices for the drugs purchased under the “Seven nosologies” programme. The massive price reduction stimulates producers to voluntarily decrease prices for other drugs that are not under FAS investigation yet; there are already 27 reductions.

Deputy Head of FAS Department for Control over Social Sphere and Trade, Nadezhda Sharavskaya stated: “As of 4 April 2017, already 378 prices for the drugs on the list of vital and essential medicines purchased at the federal level are reduced. For instance, in 2017, in view of the reduced registered prices, the minimum saving of the budgetary funds in purchasing HIV-treatment drugs will exceed 63 million RUB just for the Ministry of Health Care, while drug price reduction under the “Seven nosologies” programme will save at least 5 billion RUB”.

FAS is conducting the final Stage of the international comparative analysis of drug prices that includes monitoring vaccine prices. The preliminary results of Stage III will be summed up at the end of April 2017.